TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29807806
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts
Study: 22459241
Drug: Polyester suture
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyester suture augmentation
Study: 15995005
Drug: Vancomycin-heparin lock
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin-heparin lock solution (25 microg/mL)
Study: 7653816
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: no spinal injection
Study: 2015735
Drug: Triazolam, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam, 0.5 mg
Study: 1100300
Drug: Secobarbital, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital, 100 mg
Study: 24282870
Drug: Oral-B Triumph
Normalized name: Triumph
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Triumph with SmartGuide (oscillating-rotating brush)
Study: 11464183
Drug: Docosanol 10%
Normalized name: DOCOSANOL 10% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docosanol 10% cream
Study: 9605367
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg intramuscularly
Study: 7999289
Drug: Oral-B Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Advantage Plaque Remover
Study: 31383564
Drug: Patient Therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Therapeutic Education (PTE) combined with spa therapy
Study: 24196463
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia with 0.2% ropivacaine, ketorolac, and adrenaline followed by continuous infusion of 0.2% ropivacaine at 5 mL/hr
Study: 24196463
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia with 0.2% ropivacaine, ketorolac, and adrenaline followed by continuous infusion of saline solution at 5 mL/hr
Study: 24196463
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with saline solution followed by continuous infusion of saline solution at 5 mL/hr
Study: 19589264
Drug: Mitiglinide 10-20
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 10-20 mg three times daily
Study: 19589264
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg three times daily
Study: 11755327
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (5 mg)
Study: 11755327
Drug: Epidural S(+)‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural S(+)‐ketamine (0.1 mg/kg)
Study: 11755327
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (epidural saline and transdermal placebo)
Study: 1506656
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg)
Study: 16417534
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg twice daily
Study: 11561046
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency repetitive transcranial magnetic stimulation (HF‐rTMS) applied to the left dorsolateral prefrontal area in daily sessions for 10 consecutive working days.
Study: 8162718
Drug: Verapamil, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 40 mg every 4 h
Study: 2832763
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus iv chemotherapy (5-fluorouracil)
Study: 2832763
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus intra-arterial chemotherapy (5-fluorouracil)
Study: 18498540
Drug: Rectal challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal challenge with cow's milk protein (CM)
Study: 9383177
Drug: Hypertonic NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic NaCl solution (100 mmol NaCl in 50 ml) administered to untreated hypertensives
Study: 9383177
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (single drug or combination) for 1 month
Study: 9383177
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg in 100 ml)
Study: 9023787
Drug: Imipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (200 mg/day)
Study: 3318432
Drug: Nabumetone 1,000
Normalized name: nabumetone 1,000 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1,000 mg once daily at bedtime
Study: 21725257
Drug: Novel Baha
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel Baha implant system
Study: 21725257
Drug: Previous-generation implant
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous-generation implant system
Study: 17659605
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg twice daily
Study: 10510140
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg twice daily
Study: 9129752
Drug: Daily oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oxymetazoline (b.i.d. 150 microliters per nostril)
Study: 9129752
Drug: Daily vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vehicle (b.i.d. 150 microliters per nostril)
Study: 3503965
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate + antihistaminic + nose drops therapy
Study: 20619837
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg)
Study: 12785672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Qualitative and Quantitative feedback
Study: 2520406
Drug: Guanethidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanethidine (20 mg in 50 ml 0.5% lidocaine)
Study: 2520406
Drug: Reserpine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (1.25 mg in 50 ml 0.5% lidocaine)
Study: 2520406
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 ml 0.5% lidocaine)
Study: 28275958
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg once daily
Study: 20955637
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of mitomycin C after surgical shave excision
Study: 16705054
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at low dose (LD, 0.05 mUxmin(‐1)x100 ml(‐1))
Study: 16705054
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at intermediate dose (ID, 0.15 mUxmin(‐1)x100 ml(‐1))
Study: 16705054
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at high dose (HD, 0.30 mUxmin(‐1)x100 ml(‐1))
Study: 14744846
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (41% fat, 14% protein, 45% carbohydrates, and 7 g of fiber per 1000 kcal)
Study: 8505833
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg in adults, 0.1 mg/kg in children) with unweighted tube
Study: 3710499
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of activated charcoal
Study: 16098233
Drug: Anti-HLA-DP antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-HLA-DP antibody
Study: 11941551
Drug: Atovaquone plus
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone plus pyrimethamine (1500 mg orally twice daily + 75 mg per day after a 200‐mg loading dose)
Study: 11941551
Drug: Atovaquone plus
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone plus sulfadiazine (1500 mg orally twice daily + 1500 mg 4 times daily)
Study: 9861117
Drug: Extradural 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural 0.25% bupivacaine 4‐7 ml h‐1 and morphine 0.16‐0.28 ml h‐1
Study: 9861117
Drug: Extradural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural saline and conventional analgesics
Study: 7611794
Drug: Cyclosporine 3
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 3 mg/kg per day
Study: 29023179
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP treatment
Study: 29023179
Drug: Basal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal group (no treatment)
Study: 26502012
Drug: Long-term daily
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term daily azithromycin therapy
Study: 26066644
Drug: Olmesartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan + Calcium Channel Blocker (CCB)
Study: 26066644
Drug: Olmesartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan + Diuretic
Study: 24870737
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (pemetrexed + bevacizumab)
Study: 2037712
Drug: CMT 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT 1.5 g orally every 12 hours
Study: 2037712
Drug: CMT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT plus sucralfate 1 g orally every 6 hours
Study: 31443220
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg/kg/b.m. (CAF-9)
Study: 18042082
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine pre-bed with soluble morning insulin
Study: 18042082
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine pre-bed with soluble + NPH morning insulin
Study: 18042082
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine pre-bed with aspart + NPH morning insulin
Study: 14982565
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg before surgery, followed by 600 mg at 8, 16, and 24 hours postoperatively
Study: 6958478
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micrograms twice daily
Study: 3055745
Drug: Mobilisin ointment
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilisin ointment
Study: 15370901
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron
Study: 8281592
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg ondansetron
Study: 7978398
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ondansetron
Study: 26403472
Drug: Placebo chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo chewing tablets (identical tablets without bacteria)
Study: 16707070
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy (compared with conservative treatment)
Study: 15086644
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg once a day
Study: 15086644
Drug: Nabumetone 1,000
Normalized name: nabumetone 1,000 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1,000 mg once a day
Study: 11710708
Drug: Efficacy parameters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacy parameters of MTX treatment
Study: 9385480
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 800 mg/d
Study: 9385480
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 500 mg/d
Study: 3300312
Drug: Parenteral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral agents
Study: 28634056
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT) administered in 3 sessions with an energy flux density of 0.2, 0.4, and 0.6 mJ/mm2 (low, moderate, high intensity)
Study: 25926415
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (27.5 g of protein, 15 g of carbohydrate, and 0.1 g of fat every night before sleep)
Study: 9068738
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse therapy, 400 mg daily 1 week per month for 3 months
Study: 3816530
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase condition
Study: 29326296
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen therapy (ITB)
Study: 25493129
Drug: 4S technique
Normalized name: 4S,6S-dorzolamide
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4S technique by emergency medicine residents (EMRs)
Study: 17366357
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with normal LDL cholesterol concentrations (<3.36 mmol/L)
Study: 9796505
Drug: Treatment control
Normalized name: SALICYLIC ACID 2 g in 100 mL TOPICAL LOTION [Lqd ACNE BLEMISH TREATMENT control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment control (distilled water)
Study: 811319
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg four times a day for 14 days
Study: 811319
Drug: Deteclo 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deteclo 300 mg three times a day for 3 weeks
Study: 811319
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg four times a day for 4 days
Study: 18042892
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (30 mL)
Study: 14601471
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (Slow‐Mag B6) at 320 mg/day
Study: 14601471
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with diuretics
Study: 14601471
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with Ca channel blockers
Study: 14601471
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (Slow‐Mag B6)
Study: 10467795
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nalbuphine
Study: 10467795
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg nalbuphine
Study: 10467795
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nalbuphine
Study: 8648205
Drug: rgp160 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 vaccine
Study: 1995718
Drug: recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant hepatitis B vaccine
Study: 19436745
Drug: Mebendazole treatment
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole treatment every 3 months
Study: 19436745
Drug: Mebendazole treatment
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole treatment
Study: 2195579
Drug: Caffeine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.5 mg/kg)
Study: 31418022
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg RSV-PreF vaccine
Study: 31418022
Drug: 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg RSV-PreF vaccine
Study: 31418022
Drug: 120 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 µg RSV-PreF vaccine
Study: 29351542
Drug: Anti-adhesion gel
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-adhesion gel (hyaluronic acid-carboxymethylcellulose, Seprafilm®) applied locally during surgery
Study: 29351542
Drug: No anti-adhesion
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-adhesion gel applied (control group)
Study: 26147178
Drug: Illustrated leaflet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illustrated leaflet and verbal instructions on oral hygiene and utilization habits
Study: 1351538
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PeCT)
Study: 7952453
Drug: Expanded polytetrafluoroethylene
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanded polytetrafluoroethylene (ePTFE) patch
Study: 31797385
Drug: Psychosocial stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial stimulation intervention with weekly home visits for 18 months
Study: 16717329
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg infusion)
Study: 27926661
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusion)
Study: 16717329
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline infusion with 37 degrees C water immersion)
Study: 24745637
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment uniforms (Control)
Study: 21949754
Drug: Lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir monotherapy
Study: 20843990
Drug: Current combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current combined antiretroviral treatment (cART)
Study: 20843990
Drug: Lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir monotherapy (with treatment intensification)
Study: 19042197
Drug: Texas Christian
Normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Texas Christian University‐Treatment Motivation Assessment (TCU‐TMA)
Study: 16029399
Drug: ROC 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROC 0.25 mg.kg(‐1)
Study: 10499748
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL 1.5% lidocaine plus epinephrine 15 microg (1/200,000)
Study: 10499748
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL normal saline
Study: 1800468
Drug: Epidural fentanyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural fentanyl, 5 micrograms/mL
Study: 1800468
Drug: Epidural fentanyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural fentanyl, 5 micrograms/mL with 0.75% solution of lidocaine
Study: 31007108
Drug: Cervicitis agents
Normalized name: CERVICAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervicitis agents screening using multiplex PCR
Study: 9690805
Drug: Evening subcutaneous
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening subcutaneous administration of 5000 IU dalteparin
Study: 9690805
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 5000 IU dalteparin
Study: 9690805
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 2500 IU dalteparin
Study: 796939
Drug: Ketoprofen 200
Normalized name: ketoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 200 mg daily for 4 weeks
Study: 796939
Drug: Phenylbutazone 300
Normalized name: phenylbutazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 300 mg daily for 4 weeks
Study: 31444669
Drug: Low-frequency sonophoresis
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency sonophoresis of Chinese medicine (LFS/CM) combined with intrapleural IL-2
Study: 31444669
Drug: Low-frequency sonophoresis
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency sonophoresis of Chinese medicine (LFS/CM)
Study: 31444669
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of IL-2 (control group)
Study: 17886213
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with ACE‐i